Rating: Neutral (Avoid) | Target Price Range: RMB 70–80 (base-case SOTP basis) | Current Price: RMB 86.57 (close, 2026-10-26) | Margin of Safety: −19.1% (base-case fair-value floor vs. current price) | Time Horizon: 12 months | Market cap RMB 38.96 billion (total shares 450 million)
Pricing note: This report uses the 2026-10-26 closing price of RMB 86.57 as its valuation anchor. On the first trading day after the anchor (10-27), the stock closed at RMB 82.80; 10-28 was the Q3 earnings release date, and the stock remains in a post-event repricing channel. All multiples and percentiles in this report are computed on the frozen anchor basis.
Allist is a rare A-share innovative drug company combining a "single blockbuster product + exceptionally strong cash conversion": its core product, the third-generation EGFR-TKI furmonertinib, generated RMB 4.851 billion in sales in the first three quarters of 2026 (94.5% of revenue), driving 9M revenue of RMB 5.135 billion (+37.6%) and net profit attributable to shareholders of RMB 2.333 billion (+44.4%, already exceeding full-year FY2025). Operating cash flow coverage of net profit has exceeded 1 for four consecutive periods, with net cash-like assets of RMB 8.18 billion on the balance sheet (21% of market cap) and zero interest-bearing debt. But the other side of the coin: the growth engine is downshifting quarter by quarter (Q1 +44.2% → Q3 standalone +33.6%), the medical insurance payment price has cumulatively declined about 30%, and the 2032 expiration of osimertinib's China patent opens a category-generic window (the company's own compound patent runs to 2034), signaling an approaching earnings peak. On October 8, FURVENT (first-line global Phase III in exon-20 insertions) missed its primary endpoint, and the overseas expansion option has already been repriced (a 20% limit-down that day). This report's base-case SOTP fair value is approximately RMB 74.8/share, about 16% above the current price, with a probability-weighted expected value of approximately RMB 71.6 (−17.4%): excellent quality, a fairly full price, negatively skewed odds — Neutral/Avoid; wait for better odds from quarterly growth, the 2026 NRDL negotiation, and adjuvant therapy approval before re-entering.
Two methodological clarifications: First, 9M net profit attributable (RMB 2.333 billion) has already exceeded full-year FY2025 (RMB 2.189 billion), but revenue (RMB 5.135 billion) remains slightly below FY2025 full-year (RMB 5.187 billion, −1.0%). Second, roughly 10% of net profit attributable is non-recurring items such as government subsidies (9M non-recurring total RMB 199 million, of which subsidies of RMB 235 million are on a gross basis); the quality of adjusted-basis earnings remains solid. FCF/net profit for FY2023–FY2025 was 0.94/0.91/0.98 — textbook "book profit equals cash."
The downshift of the growth engine is an established fact (medical insurance price declining approx. 6–7% annually, third-generation penetration peaking, seven same-mechanism products competing); this report estimates furmonertinib revenue will peak in 2027–2028 (approx. RMB 7.6–8.0 billion plateau). "The market switching to peak earnings × low multiple pricing" is a risk scenario, not the base path — that low multiple (8–10x) is a stress-test assumption with no strictly comparable A-share precedent to anchor it; the offsetting hedges are golerisib (second product already ramping), adjuvant therapy, and 20ins second-line insurance inclusion. If overall revenue growth sustains ≥15% in 2027, the peak thesis will be significantly deferred.
Two residual uncertainties mean the event is not yet fully cleared: First, the coexistence of HR 0.91 in the 160mg arm and HR 0.75 in the 240mg arm, a confused dose-response relationship, means the prior probability of a "rescue via dose change/endpoint redesign" should not be overestimated (overseas covering analyst Truist has cut ArriVent's target price from $45 to $18 and removed Ex20ins value entirely). Second, the domestic same-indication Phase III (AST-NI2201) uses the same platinum-based chemotherapy control as the global trial; if the FURVENT failure stemmed partly from the control arm's BICR PFS (9.5 months) being stronger than expected, the domestic trial is exposed to the same failure mode — residual risk skews downside.
This report's probability-weighted incremental value on an rNPV basis (adjuvant RMB 2.61 billion + PACC RMB 1.85 billion + golerisib first-line RMB 170 million + 20ins residual RMB 50 million + ADC RMB 210 million, less approx. RMB 1.03 billion for double-counted golerisib second-line and existing run-rate) is approx. RMB 4.9 billion — roughly on par with the approx. RMB 5.0 billion growth premium embedded in the current price — meaning pipeline options are priced "fair to conservative" and do not constitute additional margin of safety. Restraint factors to note: the adjuvant therapy peak estimate (RMB 0.9–2.0 billion range) lacks support from complete Phase III design details, and osimertinib (ADAURA) already occupies the adjuvant standard-of-care; the PACC ORR 68.2% comes from Phase Ib single-arm data; in the 2026 NRDL negotiation, sunvozertinib applied in the same round and claims efficacy superiority, so K1 is not a one-way positive catalyst.
Computed on this report's scenario probabilities (bear 30%/base 50%/bull 20%), the probability-weighted expected value is approx. RMB 71.6, −17.4% vs. current price: negatively skewed expectations, not symmetric. The valuation conclusion is highly sensitive to the discount rate (at 9% discount, SOTP approx. RMB 88 and the conclusion flips to fair-to-undervalued; at 11%, approx. RMB 75) — the main reason we judge it "fair but full" rather than "overvalued."
| Metric | FY2023 | FY2024 | FY2025 | 9M2026 | 2026Q3 standalone |
|---|---|---|---|---|---|
| Revenue (RMB 100mn) | 20.18 | 35.58 | 51.87 | 51.35 | 18.16 |
| Revenue YoY | — | +76.3% | +45.8% | +37.6% | +33.6% |
| Net profit attributable (RMB 100mn) | 6.44 | 14.30 | 21.89 | 23.33 | 7.92 |
| Net profit attributable YoY | — | +122.0% | +53.1% | +44.4% | +40.4% |
| Adjusted net profit (RMB 100mn) | 6.06 | 13.61 | 20.22 | 21.34 | 7.68 |
| Gross margin | 96.1% | 96.0% | 96.8% | 94.9% | 95.0% |
| Net margin | 31.9% | 40.2% | 42.2% | 45.4% | 43.6% |
| Operating cash flow (RMB 100mn) | 6.75 | 15.66 | 23.23 | 24.26 | — |
| Free cash flow (OCF−CapEx, RMB 100mn) | 6.07 | 12.96 | 21.37 | — | — |
| Cash + cash-like assets (period-end, RMB 100mn) | — | — | — | 81.8 (2026-09-30) | — |
| Interest-bearing debt (period-end) | — | — | — | Only lease liabilities RMB 3.6mn | — |
| Debt-to-asset ratio | — | — | 10.4% | 11.0% | — |
| Selling expense ratio | 45.6% | 39.7% | 40.0% | 36.6% | — |
| R&D spend (RMB 100mn, % of revenue) | 3.13 (15.5%) | 4.82 (13.5%) | 5.40 (10.4%) | 4.30 (8.4%) | 1.76 (+41.5%) |
| Government subsidies in non-recurring items (RMB 100mn) | 0.21 | 0.62 | 1.84 | 2.35 | — |
Reasons for metric changes (items with YoY ≥ ±20%, with management explanations): ① 9M2026 operating cost +118.9% — the interim report attributes this to cost growth in line with furmonertinib volume growth, plus surging volumes for golerisib and pralsetinib post-NRDL inclusion; the three products have different cost and margin structures, and portfolio gross margin fell from 96.7% to 95.0%; ② FY2025 selling expenses +46.9% — expansion of the marketing team raised compensation, plus increased medical information promotion and marketing spend (composition: promotion 61% + compensation 35.5%), compounded by new team building for golerisib's launch; ③ 2026Q3 standalone R&D spend +41.5% — due to expensing of the upfront payment for the in-licensed ADC AST12608; ④ FY2025 other non-current assets +262.2% — the company used idle funds to buy large-denomination certificates of deposit over one year (RMB 2.91 billion), the balance-sheet reflection of cash accumulation; ⑤ FY2024 net profit attributable +122% — revenue ramp-up (+76.3%) combined with operating leverage release.
Q3 standalone revenue was RMB 1.816 billion (YoY +33.6%, QoQ +4.6%); net profit attributable RMB 792 million (YoY +40.4%, QoQ −12.4%, with the sequential decline mainly due to higher non-recurring gains in Q2 and R&D payment timing); adjusted net profit RMB 768 million (+40.5%). Product mix: furmonertinib standalone RMB 1.713 billion (QoQ +4.5%); golerisib approx. RMB 70 million (the second product has ramped at RMB 60–70 million for three consecutive quarters); pralsetinib promotion services contributing steadily. Quality signals: selling expense ratio down to 36.6% (−2.9pp YoY, scale effects emerging); operating cash flow of RMB 2.426 billion (+40.2%) continues to cover net profit; cash received from sales of RMB 5.69 billion exceeded revenue, accounts receivable RMB 491 million (under 10% of 9M revenue) — no channel-stuffing signs. "Beat or miss" is hard to gauge for lack of comparable post-failure sell-side commentary (search returned empty); only consensus can serve as reference: consensus FY2026E net profit of RMB 2.88 billion implies Q4 standalone of approx. RMB 550 million, YoY approx. −5%, while this report's own estimate of RMB 3.05–3.16 billion implies Q4 YoY of +25% to +44% — if our estimate proves right, the FY2026 annual report will be the first positive reconciliation point; if not, the deceleration signal will have triggered early.
Business model: A light-asset innovative drug company built on self-developed Class 1 new drugs plus in-house commercialization. Production is extremely asset-light via MAH contract manufacturing (furmonertinib entrusted to wholly-owned subsidiary Jiangsu Allist, goralsetrib entrusted to third parties); commercialization relies on an in-house, 1,700+ strong lung cancer-specialized academic promotion team plus nationwide distributor logistics (in 2025, covering 5,000+ hospitals and DTP pharmacies across 31 provinces). Revenue is essentially "innovative prescription drugs reimbursed by medical insurance"—no subscription model, no recurring contract revenue, with pricing power constrained by NRDL negotiations (historical trajectory of small annual declines). Gross margin of 95–97% is top-tier among prescription drugs.
Cash content of earnings: OCF/attributable net profit has been 1.04–1.10 for four consecutive periods, FCF/attributable 0.91–0.98—book profits are almost fully converted to cash, with neither receivables buildup (receivables balance of RMB 377 million at FY2025 year-end, slightly down YoY, 100% aged within one year) nor erosion by capex (FY2025 CapEx RMB 186 million; the capacity-building peak has passed). Non-recurring items to keep monitoring: government grants as a share of attributable net profit rose from ~3% in FY2023 to ~10% in 9M2026 (classified as non-recurring and disclosed transparently, but the trend is upward); adjusted/attributable ratio ~91%.
Return on capital: Weighted ROE of 35.4% (FY2025 disclosed); our own estimate of NOPAT/invested capital is ~25%+, far exceeding the industry cost of capital—a structural outcome of high gross margin + light assets + zero interest-bearing debt, a genuine moat signal rather than leverage-driven returns.
Capex quality: CapEx/depreciation & amortization was 4.2x in FY2025 (FY2024 6.8x, including RMB 150 million of new capacity construction, falling back after commissioning in July 2025). Incremental capital flows into capacity and clinical programs with high output per unit of investment; the company does not disclose a maintenance/growth split, but the absolute scale (~RMB 200 million per year) is trivially light against ~RMB 2.3 billion of operating cash flow.
Moat and quality red flags: Moat = differentiated clinical evidence in brain metastasis patients (FURLONG CNS PFS 20.8 vs 9.8 months) + positioning in rare mutations (first domestic approval for 20ins second-line, PACC breakthrough therapy designation) + in-house academic promotion network + gold-medal compound patent (through 2034). Three red flags: single-product dependency of 94.5% (successor products still small), top-five customers (distribution dealers) at 79.39% of sales / largest at 38.50% (distributor attribute, not end-market dependency, but concentration is high), and rising share of government grants. Additionally, R&D spending as a share of revenue has fallen to 8.4% (partly due to capitalized BD payments; the expensed R&D rate is actually ~7.4%)—low investment intensity for an innovative drug company; long-term competitiveness depends on BD in-licensing to reinforce the pipeline.
Consistency between words and deeds: pragmatic and largely delivered, but clinical statements warrant a discount. Four checkable commitment-delivery pairs: ① July 2026 IR Q&A committed ADC candidate "IND filing in China and the US simultaneously in Q3" → AST1001 received FDA IND in October 2026 (slightly delayed but delivered); ② committed to a 2026 interim dividend → implemented at RMB 270 million; ③ in the FY2025 annual report operating plan, 20ins second-line approval by Feb 2026 → delivered; adjuvant therapy NDA accepted by Sep 2026 → delivered; ④ however, before FURVENT's failure, IR consistently described the global Phase III as "progressing smoothly" with no risk warning, until the Oct 8, 2026 announcement of missing the primary endpoint—confidence in clinical-progress statements should be systematically discounted.
Shareholder friendliness: friendly to neutral. Zero secondary offerings, zero rights issues, and no convertible bonds since the 2020 IPO; total share capital of 450 million shares has never changed—zero dilution; cumulative cash dividends of RMB 922.5 million over FY2023–FY2025 (FY2025 payout ratio 20.56%), with another RMB 270 million interim dividend in 2026; in October 2026 the board approved a RMB 100–200 million buyback (cap of RMB 150/share; 0.18% of share capital repurchased at an average price of RMB 81.61–84.59)—a 20% payout ratio is not generous, but against RMB 8.18 billion of cash-like assets, the combination of dividends + buyback + BD in-licensing points in the right direction (the company responded with actions to investor-platform complaints about "holding cash without dividends or R&D").
Risk signals: No controlling-shareholder selling, no pledge financing, no abnormal related-party transactions (zero related-party transactions among top-five customers/suppliers); actual controller Du Jinhao's family and concert parties hold ~45.6%–48.6% combined—deeply aligned; the only director/officer change record is a core technical officer selling 2,000 shares in July 2026 (~RMB 250,000, no signal value). Watch: the buyback report states that the controlling shareholder and directors/officers have no selling plans for the next 6 months—the period after that commitment expires (~April 2027) is a point to observe.
| Segment/Product | FY2025 Revenue | Share | Gross Margin | YoY | First 3 Quarters of 2026 | Business Logic in One Sentence |
|---|---|---|---|---|---|---|
| Anti-tumor products (furmonertinib + goralsetrib) | RMB 5.160 billion | 99.5% | 97.28% | +47.2% | RMB 5.051 billion | Innovative prescription drugs reimbursed by medical insurance, driven by in-house academic promotion |
| —— Furmonertinib | RMB 5.120 billion | 98.7% | ~97% | +46.0% | RMB 4.851 billion (94.5% of total, +31.9%) | Third-generation EGFR-TKI, brain metastasis differentiation + multi-indication expansion |
| —— Goralsetrib (KRAS G12C) | RMB 40 million | 0.8% | — | First year on market | RMB 200 million (+394%) | In-licensed product (Jacobio), approved May 2025 and entered NRDL immediately |
| —— Pralsetinib promotion | (service revenue) | — | — | — | RMB 84 million (+130%) | Commercial promotion service revenue, leveraging channel synergy |
| Technology licensing and services | RMB 27 million | 0.5% | 9.48% | −49.1% | — | Furmonertinib overseas licensing royalties + promotion services; volatile |
The profit driver is, unsurprisingly, furmonertinib (dominating both revenue share × gross margin); goralsetrib is the only second product with meaningful scale but still under 5% of total. The gross margin structure difference (products 97.3% vs licensing/services 9.5%, a gap of nearly 88pp) stems from the latter being service/royalty revenue with no product gross margin, not from volatility in core profitability. The company is effectively a single-business company; the segment lens has only one key variable: whether furmonertinib's lifecycle management can push the peak plateau from 2027–2028 beyond 2030.
Accounting red flag (1 item, low severity): High volatility in R&D capitalization ratio—FY2023 0% → FY2024 34.7% → FY2025 23.4% → 9M2026 ~11.8%. The swings all align with the timing of BD in-licensing payments (goralsetrib upfront payment in 2024, AST12608 upfront payment of RMB 51 million capitalized in 2026Q3); the company's explanations reconcile with payment contracts, and the ratio declines year by year, with no sign of profit manipulation for now; however, this treatment means the apparent "decline in R&D expense ratio" needs to be adjusted for before interpretation.
Cross-period consistency (3 items): ① R&D capitalization ratio (above, consistent with management explanations); ② government grants/other income rising steadily (RMB 21 → 62 → 184 → 235 million, 8–10% of attributable net profit, company has not explained the trend—classified as non-recurring and transparent, but directionally reduces the "purity" of earnings); ③ OCF/attributable of 1.05/1.10/1.06/1.04, consistently above 1, with no abnormal buildup in receivables or inventory (RMB 72 million, 0.9% of total assets)—consistent.
Conclusion: Based on the three-plus periods of financial statements reviewed, apart from the two noted watch items—R&D capitalization volatility and rising government grants—no obvious accounting gimmicks or cross-period anomalies were found. Earnings quality and cash flow matching ranks in the first tier among A-share pharma companies.
Current market data (frozen anchor at Oct 26, 2026 close): Share price RMB 86.57, market cap RMB 38.96 billion; PE(TTM) 13.4x (adjusted TTM basis 14.4x), PE(TTM) of operations ex-net cash ~10.6x, PE(FY2026E, own midpoint) 12.5x, PE(FY2027E) 11.4x; PB 4.4x (37th percentile over the past 5 years). Percentile disclaimer: PE is at the 0–3% percentile over 1/3/5 years, but the company has had comparable earnings only since FY2023 (negligible profit before); the rapidly expanding denominator during the high-growth phase mechanically depresses PE—percentiles are context only, not a headline cheapness signal; the divergence between PE percentile 0% and PB percentile 37% also suggests limited informational content in percentiles. PEG cross-check: FY2026E basis 0.43, FY2027E consensus growth basis 0.94—not bubble territory.
Peer comparison (TTM basis, Oct 27, 2026):
| Company | PE(TTM) | PB | ROE (2025) | Growth Profile | Key Difference |
|---|---|---|---|---|---|
| Allist | 13.4x | 4.4x | 35.4% | 2025 +45.8% / 2026E +30% | Single-product cash cow; net cash 21% of market cap |
| Hansoh Pharmaceutical (03692.HK) | 25.1x | 4.4x | 17.3% | 2025 +22.6% | Aumolertinib RMB 5.53 billion + diversified pipeline + regularized BD out-licensing |
| Betta Pharmaceuticals (300558.SZ) | 36.1x | 2.6x | 5.0% | 2025 attributable −24.2% | "Conmana dilemma"—weak successor product profitability, high PE due to thin profits |
What the market is already pricing in: Excluding RMB 8.18 billion of net cash, the operations are valued at ~RMB 30.78 billion ≈ 9.9x own-estimate FY2026E attributable net profit, 9.4x consensus FY2027E attributable net profit. Reverse-engineering a perpetuity: RMB 30.78 billion ÷ 11% discount rate = perpetual free cash flow of ~RMB 3.4 billion/year, implying ~RMB 7.87 billion of annual sales in perpetuity, zero growth, no decay—exactly the 2027E peak sales level. In one sentence: the current price requires furmonertinib to stay on its peak plateau forever, paying essentially nothing for the 2032–2034 generic entry/patent cliff and NRDL price cuts; on the other hand, the market is not pricing total failure either (the bear case of −41% shows no corresponding trading signs; the stock stabilized at RMB 83–87 after hitting the limit-down on Oct 8).
Three-layer value (EPV): Using 2026E adjusted attributable net profit of RMB 2.83 billion (EPS RMB 6.29) as the sustainable run-rate (already includes first-year NRDL increments for 20ins second-line and goralsetrib, excludes government grants and other non-recurring items, does not extrapolate +40% growth; FCFE≈adjusted net profit, since OCF/net profit>1, capex light, zero interest-bearing debt), discounted at 11% cost of equity, EPV ≈ RMB 57.2/share (range 56.3–58.3)—the current price is ~66% covered by zero-growth EPV; of the remaining ~34% residual, net cash contributes RMB 18.18 (21%) and pipeline growth options ~RMB 11 (13%). Asset value independently estimated at ~RMB 37.1/share (net cash RMB 18.18 + conservative residual of RMB 18.9 for commercialized assets assuming rapid decay)—a floor reference for extreme scenarios, not to be summed with EPV.
SOTP (primary anchor for base-case fair value): Existing portfolio (first-line/second-line/20ins second-line + goralsetrib second-line; RMB 8.0 billion peak plateau, cliff of −25%/year from 2033) rNPV RMB 19.54 billion + adjuvant therapy RMB 2.61 billion (PoS 85%) + PACC first-line RMB 1.85 billion (domestic PoS 65% + international royalties) + goralsetrib first-line RMB 170 million (PoS 40%) + 20ins first-line residual RMB 50 million + ADC option RMB 210 million + net cash RMB 8.18 billion = RMB 33.64 billion ≈ RMB 74.8/share (after deducting ~RMB 1.03 billion of double-counting between goralsetrib second-line and the existing run-rate, adjusted to ~RMB 72.5). Anchoring basis: innovative drug assets are anchored on rNPV, discount rate 11%, with PoS and peak assumptions per asset as above; relative cross-check—RMB 74.8 corresponds to ~9.9x PE on FY2027E own-estimate attributable net profit, significantly below Hansoh at 25x and the A-share chemical formulation median of 37.9x, with the discount precisely attributable to single-product dependency and cliff visibility. Sensitivity: discount rate lowered to 9% gives SOTP ~RMB 88 (conclusion flips to reasonably slightly undervalued); cliff pushed to 2037 adds RMB 4.7 billion of existing-portfolio NPV (+RMB 10.4/share)—the valuation conclusion is most sensitive to these two parameters, which is why the judgment is "fair" rather than "overvalued."
Three scenarios and odds:
| Scenario | Probability | Fair Range (RMB) | vs. Current Price | Key Drivers |
|---|---|---|---|---|
| Bear | 30% | 48–55 (midpoint 51.5) | −40.5% | Adjuvant not approved/fails to ramp + PACC Phase III failure (FURVENT repeat) + existing portfolio peaks in 2027 then −8%/year + NRDL price cuts worse than expected |
| Base | 50% | 70–80 (midpoint 75) | −13.4% | Adjuvant approved in 2027 (peak RMB 1.5–2.0 billion) + PACC approved in 2028 + existing RMB 8.0 billion plateau through 2033 |
| Bull | 20% | 88–98 (midpoint 93) | +7.4% | Lifecycle management delays the cliff + adjuvant peak RMB 2.5 billion + positive PACC international data restarts overseas expansion + ADC licensing |
The current price sits in the upper portion between the base and bull ranges (~67th percentile); the probability-weighted expected value is ~RMB 71.6, −17.4% vs. the current price—the skew is negatively, not symmetrically, skewed: upside to the bull midpoint is only +7.4%, downside to the bear midpoint −40.5%.
In-house earnings forecast (reconciliation anchor): FY2026E revenue RMB 6.79–6.92 billion (+31%~+33%), attributable net profit RMB 3.05–3.16 billion (+39%~+44%), adjusted RMB 2.78–2.88 billion; FY2027E revenue RMB 7.8–8.4 billion (+15%~+22%), attributable net profit RMB 3.30–3.55 billion. Drivers: existing portfolio +30% / +10–15%, 20ins second-line post-NRDL RMB 250–350 million, adjuvant approved in 2027H2 contributing RMB 100–300 million, goralsetrib RMB 300 → 500–600 million; net margin 45% → 42–43% (R&D and milestone spending picking up). Against consensus (FY2026E RMB 2.88 billion / FY2027E RMB 3.28 billion), this report is ~6–10% / ~4% higher; the point of divergence is Q4 single-quarter momentum.
Conclusion: Fair to fairly valued (fair), target price RMB 70–80, safety margin −19.1% (base-case fair value floor vs. current price). Quality and price are scored separately: business quality (cash conversion, ROE, balance sheet) is first-rate; the price has fully paid for existing-product delivery, with pipeline options priced at fair to conservative levels. At 10.6x TTM ex-net cash, the operating multiple is not expensive for "single product + visible cliff," but neither is it a mispricing to exploit—this is not the moment to bet on multiple expansion, nor a short candidate (fundamental momentum still +40%; buyback and dividends provide downside support).
Industry Definition and Market Size. Allist's battlefield is China's third-generation EGFR-TKI market (oral targeted therapies for advanced NSCLC driven by first-line EGFR sensitizing mutations, second-line T790M resistance, and non-classical mutations such as 20ins/PACC). Market size: China's EGFR-TKI all-channel market was approximately RMB 20.44 billion in 2024, up 19.5% YoY (Zhongkang CMH monitoring, cited by PharmCube), with third-generation products accounting for about 88% as the absolute mainstay; over the longer term, the market grew from RMB 3.1 billion in 2017 to RMB 13.8 billion in 2022 (Frost & Sullivan basis, CAGR 34.8%), but growth has downshifted from penetration-driven high growth—the substitution of first-generation by third-generation is nearly complete (88%), and future incremental growth will come from indication expansion (adjuvant therapy, brain metastases, rare mutations) and natural growth of the patient pool; the CAGR forecast for China's anti-tumor drug market from 2023 to 2030 is 12.4% (Frost & Sullivan, cited in the company's annual report). The growth rate of the third-generation TKI sub-segment itself will be markedly lower than the overall oncology market, and the industry's nature has shifted from "growth" to "a game of existing-market share + segmented indication expansion."
Demand Base. National Cancer Center data: approximately 1.0606 million new lung cancer cases in China in 2022 (highest incidence among malignancies), NSCLC accounting for 85%; the EGFR mutation rate in Chinese NSCLC is approximately 32–40% (about 50% in adenocarcinoma)—estimated annual new EGFR-mutant NSCLC cases of approximately 250,000–360,000 (cross-validated via two approaches), compounded by continuous accumulation of existing patients as survival extends (first-line mPFS of about 20+ months followed by subsequent-line sequencing), forming the demographic foundation of the RMB 20.4 billion market. Structural changes: 20ins accounts for about 4–12% of EGFR mutations and PACC exceeds 12%; the adoption of large-panel NGS is expanding the detected population with rare mutations year by year—this is the demand source for Allist's differentiated positioning, though authoritative quantitative penetration-rate series are lacking.
Industry Chain and Value Distribution. Within the innovative drug industry chain of "R&D—clinical—registration—manufacturing—commercialization—payment," Allist keeps all high-margin activities (license-holding, academic promotion, branding) in-house: upstream API/formulation CDMO is fully competitive, and the company as MAH holder has strong bargaining power; midstream commercialization is completed via a 1,700-person in-house lung cancer team plus distributors (covering 5,000+ hospitals across 31 provinces in 2025); downstream payers are national basic medical insurance (dominant) + patient out-of-pocket + the newly established commercial insurance innovative drug list. The key bargaining weakness lies on the payment side—seven same-mechanism products put the healthcare security administration in a strong negotiating position, which is the fundamental reason why gross margins remain high but prices drift steadily downward in one direction.
Supply and Competitive Landscape. A total of 7 third-generation EGFR-TKIs have been approved: osimertinib (AstraZeneca, 2017/2019), aumolertinib (Hansoh, 2020), furmonertinib (Allist, 2021/2022), befotertinib (Betta/Inventis, 2023), rezivertinib (Beida, 2024), sunupertinib (Shenghe, 2024), and lurbinertinib (Aosaikang/Innovent, 2025). Concentration CR3 = 87.4% (2024, osimertinib + aumolertinib + furmonertinib, CM10 citing Zhongkang CMH all-channel basis); note the basis difference—under the PDB sample of grade-A hospitals, the top three totaled RMB 9.85 billion in 2024, only 48% of the all-channel total, with a high share of out-of-hospital/DTP channels; the two sets of figures must not be mixed. Share rankings (dual bases shown side by side): osimertinib at RMB 7.878 billion all-channel in 2023 (21st Century Business Herald) / RMB 5.29 billion PDB in 2024 (+1.9%, approaching a peak); aumolertinib at RMB 5.53 billion in 2025 (Cailianshe citing China Innovative Drug Sales TOP10, topping domestic products) / RMB 2.93 billion PDB in 2024 (+31.4%); furmonertinib at RMB 5.120 billion per company figures for 2025 (PDB sample RMB 1.63 billion in 2024, +97%; basis difference stems from out-of-hospital channels)—a "domestic duo" landscape has taken shape, with furmonertinib growing from RMB 236 million in 2021 to RMB 5.1 billion in five years and its share rising steadily, but growth downshifts from 2026 (H1 +33%) as expansion momentum weakens. Entry barriers: full-cycle development of Class 1 new drugs + Phase III head-to-head evidence and guideline inclusion (furmonertinib included in CSCO and 10+ other guidelines) + compound patents + medical insurance access and promotion networks—the hardest for latecomers (ranks 4–7) to replicate is the last item. No capacity bottleneck (furmonertinib 2025 production +59%, inventory +125% including charitable drug donations).
Substitution Threats and Cycle Position. Substitution threats come from mechanism iteration rather than same-class competition: the post-resistance market is being eroded by ivonescimab (PD-1/VEGF bispecific, approved in May 2024 for post-EGFR-TKI resistance), sacituzumab govitecan-class lungcan (TROP2 ADC, approved in March 2025 for previously treated EGFR-mutant), and amivantamab (EGFR/MET bispecific); fourth-generation/upgraded TKIs (Tongyuansha's TY-9591 has filed for marketing, BLU-945-class candidates in development, and Allist's in-licensed Abbisko ABK3376 in Phase I) are expected to pressure the first-line and post-resistance markets from 2027–2028. Cycle positioning: the industry is in "late growth transitioning to early maturity"; leading indicators = ① furmonertinib quarterly sales growth (stepping down: +235%→+150%→+77%→+46%→+33%); ② national reimbursement negotiation/renewal price cuts (2025 negotiation success rate 88.19%, rules of "encouraging renewals, precise price cuts"); ③ pace of new indication approvals; ④ osimertinib generics progress (Yabao holds an approval; volume ramp post-2032 patent expiry, when the category's price center will systematically shift downward).
Regulation and Policy. Direction is mostly favorable: ① "Several Measures to Support High-Quality Development of Innovative Drugs" (June 2025, 16 items) + the first commercial insurance innovative drug list (December 2025, 19 drugs) establish a dual track of "basic medical insurance covers the essentials + commercial insurance covers high-value drugs"; ② the 2026 list adjustment moved forward by about one month with pre-submission introduced for the first time, and new versions of both lists to be published before end-November—furmonertinib's 20ins second-line has been submitted; ③ the State Council's April 2026 "Opinions on Improving the Drug Pricing Formation Mechanism" grants first-launch price protection for highly innovative drugs; ④ the "15th Five-Year Plan" for the pharmaceutical industry (September 2026) lists biopharmaceuticals as an emerging pillar industry. Negative anchor: continued precise price cuts for mature indications (third-generation TKIs have not yet undergone centralized procurement, but after the 2032 osimertinib patent cliff the category faces the double pressure of generics + procurement).
Company Positioning within the Industry: Leader (one of the domestic duo) + rising share but weakening momentum. Four moats: differentiated brain penetration (FURLONG CNS PFS 20.8 vs 9.8 months, CNS ORR 91%, guideline endorsement); rare-mutation positioning (among the first domestically approved for 20ins second-line + PACC breakthrough therapy designation, though first-line first-mover advantage has been taken by sunvozertinib); commercial execution (1,700-person team with leading per-capita output, "insurance reimbursement upon launch" cadence); patents (China Patent Gold Award, valid through 2034, no self-inflicted generic risk before the 2030s). Relative weaknesses: a large gap versus Hansoh in pipeline diversification and overseas expansion (aumolertinib licensed to Glenmark, HS-20094 licensed to Regeneron for USD 2.01 billion; Allist's overseas rights essentially belong to ArriVent and have just suffered a setback).
Pipeline Overview (owned/in-licensed labeled):
| Asset | Indication | Stage | Ownership |
|---|---|---|---|
| Furmonertinib | T790M 2L / sensitizing-mutation 1L | Approved + NRDL (2021/2022) | Owned |
| Furmonertinib | 20ins 2L | Approved (Feb 2026 conditional, ORR 44.3%) | Owned |
| Furmonertinib | 20ins 1L | Global Phase III missed primary endpoint; follow-up plan under evaluation | Owned (overseas: ArriVent) |
| Furmonertinib | Adjuvant after surgery, sensitizing mutations | NDA accepted (2026-09-22) | Owned |
| Furmonertinib | PACC/L861Q 1L | Domestic Phase III + global Phase III (ALPACCA) ongoing | Owned (international: ArriVent) |
| Golecitinib (Gologerese) | KRAS G12C 2L | Approved (May 2025) + NRDL | In-licensed (Jacobio) |
| Golecitinib + SHP2 | KRAS G12C 1L | Phase III (Ph I/IIa ORR 71% / mPFS 12.2 months) | In-licensed |
| AST1001 | EGFR/c-MET bispecific ADC, solid tumors | FDA IND approved (2026-10-24), global Phase I | Owned |
| AST12608 | MUC16/NaPi2b tetravalent ADC, gynecologic tumors | FDA IND May 2026; China rights in-licensed (2026Q3) | In-licensed (ArriVent) |
| AST2303 | Next-generation EGFR small molecule | Early stage (in-licensed from Abbisko) | In-licensed |
Core Asset rNPV and SOTP (see "Valuation and Odds" section): existing portfolio RMB 19.54 billion (RMB 8.0 billion peak-sales platform, −25%/yr cliff from 2033), adjuvant RMB 2.61 billion (peak RMB 1.5–2.0 billion, PoS 85%), PACC RMB 1.85 billion (peak ~RMB 1.8 billion, domestic PoS 65%), golecitinib 1L RMB 170 million (PoS 40%), 20ins 1L residual RMB 50 million, ADC options RMB 210 million, net cash RMB 8.18 billion; total RMB 33.64 billion ≈ RMB 74.8/share (≈ RMB 72.5/share after correcting golecitinib double-counting). The three most sensitive parameters: discount rate (±2pp ≈ ±RMB 13/share), cliff timing (2033 vs 2037 ≈ RMB 10.4/share), adjuvant peak (±RMB 500 million ≈ ±RMB 1/share). Primarily bottom-up; sell-side consensus used only for reference (no post-failure target-price sample).
Clinical Milestone Calendar (Binary Events over the Next 12–24 Months):
Magnitude assessment of each event: Nov 2026 NRDL negotiation (20ins 2L inclusion → RMB 150–350 million incremental in 2027, +5–12%; rejection/deep cut −3–5%); adjuvant approval (2027Q1–Q2, +8–15%); FURVENT follow-up plan (2027H1, positive repair +10–20% / abandonment −5–10%); golecitinib 1L Phase III (2027H2, +15–25% / −10–15%); ALPACCA (2028, +20–30% / −10–15%—the largest hedge against the FURVENT failure).
Cash Runway: net cash-like RMB 8.18 billion vs annualized R&D + administrative expenses of ~RMB 700 million—runway of 10+ years, no refinancing dilution risk; supports parallel execution of dividends + buybacks + BD in-licensing.
Competitive Standing within Same-Mechanism Landscape: 20ins 1L—sunvozertinib's global Phase III already positive with global licensing completed (USD 600 million upfront); furmonertinib has largely exited the first-mover race; 20ins 2L—two approvals in the same cohort competing in-market; PACC 1L—furmonertinib is one of the global Phase III advancers with clear first-mover positioning (FURTHER Ib ORR 68.2% as prior); KRAS G12C—a multi-way scramble among Amgen's sotorasib / Innovent's garsorasib / Jacobio's self-developed candidate; golecitinib 2L already in NRDL, and the 1L combination could take the lead if it hits (Innovent's FAK combination Phase III is at a similar stage; readout order determines elasticity); ADC—data all at pre-Phase I stage, watch the first safety and efficacy signals by end-2027.
Investment Judgment: Neutral (avoid), confidence 0.55, time horizon 12 months. Allist's business quality ranks among the top of A-share innovative drug companies (profit cash conversion >1, ROE 35%, zero debt, net cash at 20% of market cap), but the current price of RMB 86.57 has already fully paid for the monetization of existing assets: base-case SOTP fair value RMB 70–80, probability-weighted expectation RMB 71.6 (−17.4%), margin of safety −19.1%. Two-thirds of the price structure is covered by the zero-growth earnings value; the market does not owe this company a valuation re-rating—what is needed is new evidence.
Strategy: Non-holders should avoid chasing and wait for two better-odds setups—first, the price returning to the RMB 70–80 base fair-value range (~10–11.5x 2026E PE) without a stall in quarterly growth; second, adjuvant approval + NRDL volume ramp pushing peak sales beyond 2030 (duration re-rating). Holders can use buyback support (executed at RMB 81.6–84.6) and dividends (yield ~1.6%) to trim positions in batches as catalysts materialize.
Key Risk Warnings: Confirmation of a stall if furmonertinib's Q4-2026 single-quarter growth falls below 25%; exclusion of 20ins from the 2026 NRDL negotiations or 1L/2L renewal price cuts exceeding 20% in 2027; AST-NI2201's domestic Phase III exposed to the same failure mode as FURVENT; early pricing-in of the category price-center shift after the 2032 osimertinib patent expiry.
Tracking and Verification (Next 12 Months): Nov 2026 NRDL list publication (20ins 2L negotiated price) → Apr 2027 annual report (Q4 product-level revenue reconciliation, 2026 payout ratio) → 2027Q1–Q2 adjuvant review outcome → 2027H1 FURVENT follow-up plan and OS data → 2027H2 golecitinib 1L Phase III readout. Price dimensions: a break below RMB 80 (return to fair-value range) prompts a re-check of the neutral stance; below RMB 70 (lower bound of fair range) re-evaluate entry value; below RMB 48 (lower bound of bear case) treat the investment thesis as fully broken and reassess comprehensively; a rise above RMB 98 implies the market has priced the bull scenario and upside is exhausted.
This report's valuation anchor is the 2026-10-26 closing price of RMB 86.57; financial data as of the 2026 Q3 report (disclosed 2026-10-28). Key sources: Allist periodic reports and announcements (cninfo), National Healthcare Security Administration, Zhongkang CMH / PharmCube, Frost & Sullivan, Cailianshe, The Paper, BioSpace, ASCO abstracts.